CCR5 and graft versus host disease: CCR5 is a chemokine receptor involved in GVHD pathogenesis as clearly demonstrated in murine models [90,91]; Maraviroc, a CCR5 antagonist, appeared promising in the reduction of severe aGVHD in the liver and gut in a phase 2 clinical study [92].